InCarda Therapeutics

Coming – June 4

Closing The $1.5B Gap In AFib Cardioversion Therapy

Date and Time

June 4

–

4:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

More than 10 million Americans live with Atrial Fibrillation today. Yet, current treatments focus on managing symptoms through long-term medication with significant side effects.

InCarda Therapeutics is building a new approach to treating A-fib at the moment patients need help most: when an episode begins. The company is developing rapid, safe pharmacologic cardioversion therapies designed to restore normal heart rhythm both in the hospital and, ultimately, at home, potentially avoiding emergency admissions, anesthesia, and prolonged hospital stays.

InCarda combines two well-understood anti-arrhythmic medicines into a treatment that is greater than the sum of its parts; a fast-acting therapy that converts A-fib quickly and safely, addressing a major gap in today’s standard of care.

Join our online event with InCarda President and CEO, Dr. Myles Greenberg, to hear how their approach has the potential to fill the $1.5B market opportunity for eligible AFib cardioversion patients.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.